Business Information
The group’s principal activities include developing and commercializing bioactive drug device combination products. The groups provide their product for periodontal, orthopedic, spine sports injury and cranio maxillofacial. The group products sold under the trade name GEM 21(R), GEM 21A(TM), GEM OS(R), GEM(R), GEM C(TM), GEM LT(TM) and OsteoMimetic(TM). The group operates from the United States. The revenue of the group for the year 2006 was $4,133,939.
|
|
Name |
Title
|
Email
|
| Larry Papasan | Chmn. | N/A | | Charles Hart | Chief Scientific Officer, VP | N/A | | Larry Bullock | CFO | N/A | | James Monsor | VP - Operations | N/A | | Mark Citron | Sr. VP - Regulatory Affairs, Quality Systems | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 4,134 | (17,064) | | 2005 | 4,517 | (11,676) | | 2004 | 5,601 | (1,043)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
